Digital extensor muscle aplasia-polyneuropathy Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

💰

1Open funds

Regulatory Watchboard

1 event

Jul 1983

Panhematin: FDA approved

Digital extensor muscle aplasia-polyneuropathy

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

Panhematin

Abbott Laboratories

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Panhematin

(Hemin)Orphan drug

Abbott Laboratories

12.1 Mechanism of Action Heme acts to limit the hepatic and/or marrow synthesis of porphyrin. This action is likely due to the inhibition of δ-aminole...

Approved Jul 1983FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Digital extensor muscle aplasia-polyneuropathy.
Search all trials →

Search clinical trials for Digital extensor muscle aplasia-polyneuropathy →

Recent News & Research

No recent news articles indexed yet for Digital extensor muscle aplasia-polyneuropathy.
Search PubMed for Digital extensor muscle aplasia-polyneuropathy →

Browse all Digital extensor muscle aplasia-polyneuropathy news →

Specialist Network

No specialists currently listed for Digital extensor muscle aplasia-polyneuropathy.

View all Digital extensor muscle aplasia-polyneuropathy specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰